China Resources Pharmaceutical Group Ltd. (HK:3320)
:3320
Top Page
China Resources Pharmaceutical Group Ltd.
(3320)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$5.00
▲(8.46% Upside)
Action:ReiteratedDate:10/24/25
The overall stock score of 61 for HK:3320 reflects a balanced but cautious outlook. Financial performance, the most significant factor, shows strong revenue growth but is weighed down by thin margins and declining cash flow. Valuation is a positive with a reasonable P/E ratio and decent dividend yield, while technical indicators suggest neutral momentum with no strong trend. Investors should monitor profitability and debt levels closely.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term expansion and stability.
Negative Factors
Declining Net Profit Margins
Declining net profit margins indicate pressure on profitability, which can affect long-term earnings potential and shareholder value if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term expansion and stability.
Read all positive factors
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$39.39B
Dividend Yield2.95%
Average Volume (3M)13.76M
Price to Earnings (P/E)6.4
Beta (1Y)0.76
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees72,700
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume13,454,154
30 Day Avg. Volume13,759,791
Financial Highlights & Ratios
PEG Ratio-0.57
Price to Book (P/B)0.70
Price to Sales (P/S)0.13
P/FCF Ratio2.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.72Price Target Upside45.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The compan...
How the Company Makes Money
China Resources Pharmaceutical Group Ltd. generates revenue through multiple key streams, including the manufacturing and sale of pharmaceutical products, which constitutes a significant portion of its income. The company also earns from its distr...
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
55
Neutral
Cash Flow
60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 281.84B | 274.18B | 270.40B | 254.11B | 236.81B | 200.42B |
| Gross Profit | 44.59B | 43.30B | 42.18B | 39.13B | 35.38B | 32.29B |
| EBITDA | 15.71B | 15.45B | 15.43B | 15.47B | 11.95B | 12.47B |
| Net Income | 3.07B | 3.57B | 3.85B | 3.50B | 3.08B | 2.78B |
Balance Sheet | ||||||
| Total Assets | 314.32B | 274.28B | 271.48B | 243.93B | 248.56B | 209.37B |
| Cash, Cash Equivalents and Short-Term Investments | 34.54B | 17.48B | 59.27B | 32.52B | 37.32B | 52.34B |
| Total Debt | 90.96B | 73.43B | 62.16B | 63.85B | 67.96B | 55.20B |
| Total Liabilities | 191.56B | 169.90B | 169.20B | 150.24B | 152.69B | 128.69B |
| Stockholders Equity | 54.75B | 51.34B | 50.60B | 49.56B | 50.98B | 46.47B |
Cash Flow | ||||||
| Free Cash Flow | 17.88B | 14.55B | 12.42B | 7.54B | 8.32B | 4.06B |
| Operating Cash Flow | 21.15B | 17.55B | 15.55B | 10.90B | 11.22B | 6.28B |
| Investing Cash Flow | -8.37B | -8.89B | -2.07B | -3.30B | -8.83B | -2.02B |
| Financing Cash Flow | -13.39B | -16.84B | -4.07B | -9.00B | 5.31B | -3.60B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
Positive
4.61
Price Trends
4.72
Positive
4.71
Positive
4.88
Positive
Market Momentum
0.37
Negative
86.61
Negative
98.69
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3320, the sentiment is Positive. The current price of 4.61 is below the 20-day moving average (MA) of 4.95, below the 50-day MA of 4.72, and below the 200-day MA of 4.88, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 86.61 is Negative, neither overbought nor oversold. The STOCH value of 98.69 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:3320.
China Resources Pharmaceutical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$25.63B | 22.15 | 7.26% | 3.13% | 10.56% | -13.58% | |
70 Outperform | HK$31.78B | 11.61 | 14.47% | 4.09% | -0.45% | 9.00% | |
63 Neutral | HK$34.96B | 19.33 | 8.60% | 2.26% | 11.78% | 19.06% | |
61 Neutral | HK$39.39B | 6.37 | 7.91% | 2.95% | ― | ― | |
59 Neutral | HK$40.60B | 8.90 | 7.89% | 7.15% | 1.13% | -13.53% | |
57 Neutral | HK$75.74B | 14.15 | 7.02% | 1.69% | -1.12% | 76.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3320
China Resources Pharmaceutical Group Ltd.
6.27
1.70
37.08%
HK:0867
China Medical System Holdings
14.33
7.38
106.19%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
17.21
2.04
13.48%
HK:1513
Livzon Pharmaceutical Group
29.20
4.54
18.40%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
20.80
7.91
61.39%
HK:0512
Grand Pharmaceutical Group Limited
7.22
1.88
35.21%
China Resources Pharmaceutical Group Ltd. Corporate Events
China Resources Pharmaceutical Delays Circular on 2026–2028 Sales Framework Agreement
Jan 9, 2026
China Resources Pharmaceutical Group Limited has announced a delay in sending to shareholders a circular related to its sales framework agreement for 2026–2028 with China Resources Healthcare Group Limited. The circular, which will include d...
China Resources Pharma Renews Connected Energy Supply Deal for Southern China Plant
Dec 30, 2025
China Resources Pharmaceutical Group Ltd. has arranged for its subsidiary CR Sanjiu Chenzhou to continue sourcing energy for heating and cooling, steam and electricity from CR Gas Chenzhou, an indirect wholly owned subsidiary of China Resources Ga...
China Resources Pharmaceutical Finalises Setup of Biotech-Focused Investment Fund
Dec 30, 2025
China Resources Pharmaceutical Group has completed the regulatory registrations and industry association filings required to establish a new private investment fund in mainland China, securing a filing record from the Asset Management Association ...
China Resources Pharmaceutical Extends Property Leasing and Management Deal With Controlling Shareholder
Dec 22, 2025
China Resources Pharmaceutical Group Ltd. has entered into a supplemental framework agreement with its controlling shareholder, China Resources (Holdings) Co. Ltd. (CR Holdings), under which the CR Holdings Group will continue to lease properties ...
China Resources Pharmaceutical Signs New Sales Agreement with CR Healthcare
Dec 16, 2025
China Resources Pharmaceutical Group Ltd. has announced the signing of a new Sales Framework Agreement with CR Healthcare, effective from January 1, 2026, to December 31, 2028. This agreement, which involves connected transactions due to the relat...
China Resources Pharmaceutical and CR Medical Extend Supply Chain Collaboration
Dec 16, 2025
China Resources Pharmaceutical Group Ltd. and CR Medical Group have entered into a new Cooperation Framework Agreement for 2026/2028 to continue their collaboration on supply chain management services. This agreement aims to enhance the efficiency...
China Resources Pharmaceutical Completes First Tranche of Medium Term Notes 2025
Dec 15, 2025
China Resources Pharmaceutical Group Ltd. has announced the successful issuance of the first tranche of its Medium Term Notes 2025, amounting to RMB3 billion with a 3-year term and a coupon rate of 2.19% per annum. The proceeds from this issuance ...
China Resources Pharmaceutical Group Ltd. Announces New Framework Loan Agreements
Dec 15, 2025
China Resources Pharmaceutical Group Ltd. has entered into new Framework Loan Agreements for the period from January 1, 2026, to December 31, 2028, with CRI and CR Holdings, both of which are connected entities to the company. These agreements, wh...
China Resources Pharmaceutical Announces Change in Company Secretary
Dec 15, 2025
China Resources Pharmaceutical Group Ltd. announced a change in its company secretary and authorized representative, effective December 15, 2025. Ms. Cheng Kwai Yuk resigned from her roles, with no disagreements with the board, and Ms. Wan Wing Yi...
China Resources Pharmaceutical Group Updates Business Travel Services Agreement
Dec 10, 2025
China Resources Pharmaceutical Group Ltd. has entered into the Amended Business Travel Services Framework Agreement 2026 with CR Digital, a wholly-owned subsidiary of its controlling shareholder, CRI. This agreement, effective from December 10, 20...
China Resources Pharmaceutical Group’s Subsidiary Secures Approval for Medium Term Notes Issuance
Dec 1, 2025
China Resources Pharmaceutical Group Ltd. announced that its subsidiary, CR Pharmaceutical Commercial, has received approval from the National Association of Financial Market Institutional Investors to issue medium term notes in China. The registr...
China Resources Pharmaceutical Proposes Amendments to Articles of Association
Nov 27, 2025
China Resources Pharmaceutical Group Ltd. has announced proposed amendments to its Articles of Association, aiming to align with the latest legal and regulatory requirements concerning treasury shares and shareholder communication. These changes a...
China Resources Pharmaceutical Completes Second Tranche Bond Issuance
Nov 18, 2025
China Resources Pharmaceutical Group Ltd. has successfully completed the public issuance of the second tranche of its 2025 Corporate Bonds in the PRC, raising RMB1.1 billion. The proceeds will be utilized for various operational expenses, includin...
China Resources Pharmaceutical Group Forms RMB500 Million Investment Fund
Oct 30, 2025
China Resources Pharmaceutical Group Ltd. has announced the formation of a new fund with a proposed size of RMB500 million, aimed at investing in high-growth enterprises in synthetic biology, innovative drugs, and biotechnology. The company’...
CR Boya Bio-pharmaceutical Reports Nine-Month Financial Results
Oct 27, 2025
CR Boya Bio-pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a revenue increase to RMB 1.47 billion compared to th...
CR Sanjiu Reports Revenue Growth Amid Profit Decline in 2025 Q3
Oct 24, 2025
CR Sanjiu reported its unaudited financial results for the nine months ending September 30, 2025, showing a revenue increase to RMB 21.99 billion from RMB 19.74 billion in the previous year, despite a decline in net profit to RMB 2.90 billion from...
Jiangzhong Pharmaceutical Reports Increased Profit Amid Revenue Dip
Oct 24, 2025
Jiangzhong Pharmaceutical, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company saw a slight decrease in revenue compared to the previous year, bu...
KPC Pharmaceuticals Reports Decline in Revenue and Profit for 2025
Oct 24, 2025
KPC Pharmaceuticals, Inc., partially owned by China Resources Pharmaceutical Group Ltd., reported a decrease in revenue and net profit for the nine months ending September 30, 2025, compared to the previous year. The financial results indicate a n...
Dong-E-E-Jiao Reports Strong Nine-Month Financial Performance
Oct 24, 2025
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its unaudited financial results for the nine months ending September 30, 2025. The company saw an increase in revenue and net profit compared to the previous year, ...
CR Double-Crane Reports Stable Financials Amid Revenue Decline
Oct 24, 2025
CR Double-Crane, a subsidiary of China Resources Pharmaceutical Group, reported its unaudited financial results for the nine months ending September 30, 2025. The company experienced a slight decline in revenue and net profit compared to the previ...
Tasly Pharmaceutical’s Nine-Month Financials Show Increased Profit
Oct 24, 2025
Tasly Pharmaceutical reported its unaudited financial results for the nine months ending September 30, 2025, showing a slight decrease in revenue but a notable increase in net profit compared to the previous year. The financials reveal a positive ...
China Resources Pharmaceutical Completes First Tranche of 2025 Bond Issuance
Oct 21, 2025
China Resources Pharmaceutical Group Ltd. announced the successful issuance of the first tranche of its 2025 corporate bonds in China, amounting to RMB1.1 billion with a 1.82% annual coupon rate. The proceeds will be used for various operational a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.